top of page
Publications
Peer-reviewed research from RS Oncology and our academic collaborators advancing the science behind PRX3 inhibition in cancer.
Nature Communications
Jul 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
Gibson V, Dzialo J, Messier T, Bzura A, Poile C, Rogel J, Hahne JC, Habibovic A, Stead S, Saaman A, Blyth KG, Szlosarek PW, Lord S, Thistlethwaite F, Zhang M, Nakas A, Wells-Jordan P, Kutywayo K, Butnor KJ, Heintz NH, Naumov GN, Dungey M, Herrero Colomina J, Aktas B, Dulloo S, Spicer J, Fennell DA & Cunniff B.
bottom of page